Our Science


G-Protein Coupled Receptors (GPCRs) are a large family of cell surface receptors that respond to a variety of external signals. Close to 30% of currently marketed drugs target this receptor family. 


The forefront of GPCR research has shifted in recent years from the constraints of traditional orthosteric receptor-ligand interactions towards an understanding of the importance of allosterism, biased ligands and persistent signaling.  Beacon scientists have extensive experience in all these emerging approaches. In addition, the revolution in GPCR structural biology has enabled significant advances in both biophysical methods and computational modeling of receptors.


We have a broad array of high throughput and targeted assay platforms addressing emerging GPCR biology, a well characterized diverse compound collection, state-of-the-art computational approaches, and a broad range of in vivo pharmacology expertise and capabilities. Our assets and experience enable us to leverage these recent scientific advances and more efficiently drive drug discovery.


Beacon Discovery was founded to take advantage of a unique collection of expertise in GPCR drug discovery within a group of dedicated scientists who have worked together for more than fifteen years.  Over the course of our careers, we have delivered in excess of 20 compounds into clinical testing.

We believe that no other company can boast the experience or expertise of Beacon Discovery in the field of GPCR research.  We use proprietary know-how and lessons learned from our years of experience with this target class to discover novel chemical matter for intractable GPCRs that have, to date, eluded traditional HTS screening approaches. Our team retains expertise in all aspects of GPCR drug discovery including: medicinal and computational chemistry, high throughput screening, in vitro and in vivo pharmacology.

We are working in collaboration with several Big Pharma partners in the areas of CNS, GI and metabolism and have internal projects that focus on orphan receptors in the CNS to treat diseases with unmet medical need.  Since our inception we have significantly expanded our team and expanded our facilities to accommodate our growing partnerships.